The Journal of clinical endocrinology and metabolism · 2025
Clinical Features, Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome).
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaewkrasaesin Chatchon, Hwang Michael, Vasandani Chandna, Brown Rebecca J, Garg Abhimanyu
Аннотация
CONTEXT: Acquired partial lipodystrophy (APL) is an ultra-rare disorder characterized by unique loss of subcutaneous fat affecting mostly the face, neck, trunk, and upper extremities. The precise prevalence of metabolic derangements and other comorbidities among patients with APL is not clear.
OBJECTIVE: We report clinical features and metabolic and autoimmune derangements in a large cohort.
METHODS: A total of 86 participants (77 female, 9 male; median age 40 years [range 8-78 years]) with APL from 2 US tertiary referral centers, UT Southwestern and National Institute of Diabetes and Digestive and Kidney Diseases, were recruited into prospective observational studies. Demographic, health history, and laboratory data at the initial evaluation and follow-up were systematically collected and analyzed.
RESULTS: The median age of onset of lipodystrophy was 7 years (range, 2-51 years). About 15% had autoimmune diseases, 38% had either diabetes mellitus or glucose intolerance, 43% had hypertriglyceridemia, and 61% had fatty liver or metabolic dysfunction-associated steatohepatitis (MASH). A total of 71% of patients had low serum complement 3 (C3) levels, 8% had membranoproliferative glomerulonephritis, while drusen occurred in 62% of those with fundus examination (n = 21). Patients with C3 hypocomplementemia, compared to those with normal serum C3 level, reported earlier onset of diabetes or glucose intolerance (median age 36 vs 56.5 years, P = .007), hypertriglyceridemia (30 vs 48 years, P = .03), and drusen (33 vs 60 years, P = .14).
CONCLUSION: Our data reveal high risk of metabolic comorbidities and drusen in patients with APL, with earlier onset of these complications in those with C3 hypocomplementemia.
OBJECTIVE: We report clinical features and metabolic and autoimmune derangements in a large cohort.
METHODS: A total of 86 participants (77 female, 9 male; median age 40 years [range 8-78 years]) with APL from 2 US tertiary referral centers, UT Southwestern and National Institute of Diabetes and Digestive and Kidney Diseases, were recruited into prospective observational studies. Demographic, health history, and laboratory data at the initial evaluation and follow-up were systematically collected and analyzed.
RESULTS: The median age of onset of lipodystrophy was 7 years (range, 2-51 years). About 15% had autoimmune diseases, 38% had either diabetes mellitus or glucose intolerance, 43% had hypertriglyceridemia, and 61% had fatty liver or metabolic dysfunction-associated steatohepatitis (MASH). A total of 71% of patients had low serum complement 3 (C3) levels, 8% had membranoproliferative glomerulonephritis, while drusen occurred in 62% of those with fundus examination (n = 21). Patients with C3 hypocomplementemia, compared to those with normal serum C3 level, reported earlier onset of diabetes or glucose intolerance (median age 36 vs 56.5 years, P = .007), hypertriglyceridemia (30 vs 48 years, P = .03), and drusen (33 vs 60 years, P = .14).
CONCLUSION: Our data reveal high risk of metabolic comorbidities and drusen in patients with APL, with earlier onset of these complications in those with C3 hypocomplementemia.